Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The serum 25(OH)D was positively associated with age, and the serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Full studies
Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Study design awaiting verification · Breast Cancer (Tokyo, Japan) · 2021
Original publication title
Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Study background
What background does the paper provide?
Vitamin D is a fat-soluble secosteroid with well-established effects on calcium homeostasis, and it is the precursor to the potent steroid hormone calcitriol [1, 2]. Deficiency of vitamin D is associated with increased risks of morbidity and mortality in various diseases including cardiovascular, malignant, and autoimmune diseases [2Not reported5]. Vitamin D regulates numerous cellular pathways such as inhibition of cellular proliferation, inflammation, invasion, metastasis and angiogenesis, and also promotion of apoptosis and differentiation [2].
One of those mechanisms is the intervention on the cell cycle via kinases such as cyclins, cyclin-dependent kinases (CDKs) and CDK physiological modulators [6]. Previous studies have revealed that the vitamin D deficiency was associated with poor outcomes in breast cancer [7Not reported9], although contradictory results have also been reported [10, 11].
25-hydroxvitamin D (25(OH)D) is the circulating form of vitamin D that is measured in the blood and clinically used to establish and monitor the vitamin D status. One study showed that the serum 25(OH)D levels could predict cancer survival in a prospective cohort with measurements prior to and at the time of cancer diagnosis [12].
Neoadjuvant chemotherapy (NAC) has become a standard of care not only in locally advanced breast cancer, but in early breast cancer, especially for patients with large tumor size, lymph node metastasis, HER2 overexpression and triple negative breast cancer (TNBC) subtype. Pathological complete response (pCR) is associated with improved prognosis. This association appears stronger in the HER2+ /hormone receptor (HR): or TNBC subtype [13, 14].
Recently, a statistically significant association between 25(OH)D level at baseline and pCR in patients with receiving NAC has been reported [15, 16]. However, other studies reported that there was no effect of serum 25(OH)D levels on the pathologic complete response (pCR) in neoadjuvant settings [17Not reported19].
Recent reports shows that East Asian countries have high prevalence rates of Vit D deficiency [20, 21]. However, in Japan, the importance of the vitamin D on the incidence of cancer or the prognosis of the patients with malignancies has not been recognized so much. There are few studies on the association between serum vitamin D levels and the clinicopathological features and the prognosis of the Japanese women with breast cancer. In the present study, we retrospectively compared serum 25(OH)D level at baseline and the efficacy of NAC and the prognosis after surgery.
Source: Introduction Source: Introduction Source: Introduction Source: Introduction Source: IntroductionStudy methods
What methods does the paper describe?
Patient population
A total of 250 patients with clinical Stage I: III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery of the breast and axilla in the Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, between 2009 and 2019 were included in this study. Chemotherapy was administered according to the standard regimens of anthracyclines and/or taxanes with or without trastuzumab for HER2-positive (HER2+) breast cancer. For all these patients, serum obtained just before starting NAC was available.
The clinical data were obtained from the patients’ medical records. The anatomical AJCC/UICC TNM classification and stage groupings were used. This study was approved by the institutional review board of our hospital, and was in accordance with the Declaration of Helsinki. The serum was the surplus sample from the usual blood test. We obtained the written informed general consent from an individual patient before the start of the treatment and the sample acquisition. Our IRB waived the requirement for obtaining another written informed consent when we use the surplus samples.
Pathological examinations
All pathological examinations were performed by the experienced pathologists in our hospital. The expression of estrogen receptor (ER) and progesterone receptor (PgR) was regarded as positive if the nuclear expression was ≥ 1%. The HER2 status was evaluated according to the recommendation of ASCO/CAP [22]. The pCR was regarded as the total disappearance of invasive carcinoma cells, including lymph nodes, regardless of the presence of residual ductal carcinoma in situ. If ER and /or PgR were positive, it was defined HR-positive (HR+).
The tumor subtypes were divided into the following four groups; HR+ /HER2−, HR+ /HER2+ , HR−/HER2+ and triple negative (TN; ER−, PgR− and HER2−).
Serum vitamin D (25-hydroxyvitamin D; 25(OH)D) levels
Serum samples obtained before the first cycle of NAC were stored at − 30 °C until analysis. Serum 25(OH)D levels were analyzed by ELISA at SRL laboratories (Tokyo, Japan). Serum 25(OH)D levels were defined as ‘sufficient’ if serum 25(OH)D ≥ 20 ng/mL and ‘insufficient’ if serum 25(OH)D < 20 ng/mL [2, 19].
Statistical analyses
The statistical analyses were performed using the JMP software package, version 14.0 (SAS Institute Inc., Cary, NC, USA). The associations between the clinicopathological characteristics were assessed using χ2 tests. The time to recurrence (TTR) was defined as the time from surgery to the first breast cancer event, including loco-regional recurrence, distant metastasis or a new cancer in the contralateral breast. The time to distant recurrence (TTDR) was defined as the time from the date of curative surgery to the detection of distant recurrence.
The overall survival (OS) was defined as the time from the date of curative surgery to death. Survival curves were plotted using the Kaplan: Meier method, and the association between the survival and each variable was determined by the log-rank test. For multivariate analysis of the survival data, Cox proportional hazards model was used. Differences were considered to be significant at P < 0.05.
Results: Patients’ characteristics
The clinicopathological characteristics of the patients included in this study were shown in Table 1. The median age was 59 years (range 28 to 75). Pre/peri-menopausal and postmenopausal women were 135 (54.0%) and 115 (46.0%), respectively. About 60% of the patients were at clinical stage II. The rate of ER, PgR and HER2-positivity was 69.6%, 48.0% and 39.2%, respectively. In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively.
Among the 250 patients, pCR was achieved in 60 (24.0%) patients.
Clinicopathological characteristics of the patients
| Factors | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 59 (28 to 75) |
| Menopausal status | |
| Pre/perimenopause | 135 (54.0) |
| Postmenopause | 115 (46.0) |
| Clinical stage | |
| I | 6 (2.4) |
| IIA | 73 (29.2) |
| IIB | 89 (35.6) |
| IIIA | 21 (8.4) |
| IIIB | 24 (9.6) |
| IIIC | 37 (14.8) |
| Nuclear grade | |
| 1, 2 | 185 (74.6) |
| 3 | 63 (25.4) |
| ER | |
| Negative | 76 (30.4) |
| Positive | 174 (69.6) |
| PgR | |
| Negative | 130 (52.0) |
| Positive | 120 (48.0) |
| HER2 | |
| Negative | 152 (60.8) |
| Positive | 98 (39.2) |
| Subtype | |
| HR+/HER2− | 111 (44.4) |
| HR+/HER2+ | 67 (26.8) |
| HR−/HER2+ | 31 (12.4) |
| TN | 41 (16.4) |
| Pathological efficacy | |
| pCR | 60 (24.0) |
| Non-pCR | 190 (76.0) |
| 25(OH)D | |
| Insufficient (< 20 ng/mL) | 241 (96.4) |
| Sufficient (≥ 20 ng/mL) | 9 (3.6) |
ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D
Relationships between the serum 25(OH)D level and the clinicopathological characteristics
Results: Relationships between the serum 25(OH)D level and the clinicopathological characteristics
The median 25(OH)D levels were 10.7 ng/mL (range 3.0 to 26.6 ng/mL). Surprisingly, serum 25(OH)D was sufficient in only nine patients (3.6%) in this cohort (Table 1). Serum 25(OH)D was positively associated with age (P = 0.0016), and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women (P = 0.0020, Fig. 1). In the present study, serum 25(OH)D level was divided into two groups, low and high, using a dichotomous variable at the median value 10.7 ng/mL.
Relationships between the serum 25(OH)D level and the clinicopathological characteristics were shown in Table 2. The median age of the high 25(OH)D group was significantly higher than that of the low 25(OH)D group (52.7 ± 0.93 year old vs. 48.5 ± 0.93, P = 0.0015), and the number of the postmenopausal women was significantly higher in the high 25(OH)D group (P = 0.0022). There were no significant associations between serum 25(OH)D level and the clinical stage, ER and PgR expressions, HER2 status and tumor subtypes. Relationship between age and menopausal status and the serum 25(OH)D level. A Relationship between age and the serum 25(OH)D level. B Relationship between menopausal status and the 25(OH)D level
Relationships between the clinicopathological characteristics and the serum 25(OH)D level
| Factors | 25(OH)D low (n = 124) | 25(OH)D high (n = 126) | P value |
|---|---|---|---|
| Age (years) | |||
| Mean ± SE | 48.5 ± 0.93 | 52.7 ± 0.93 | 0.0015 |
| Menopausal status | |||
| Pre/perimenopause | 79 (63.7) | 56 (44.4) | 0.0022 |
| Postmenopause | 45 (36.3) | 70 (55.6) | |
| Clinical stage | |||
| I | 2 (1.6) | 4 (3.2) | 0.147 |
| IIA | 35 (28.3) | 38 (30.2) | |
| IIB | 40 (32.3) | 49 (38.9) | |
| IIIA | 10 (8.1) | 11 (8.7) | |
| IIIB | 11 (8.9) | 13 (10.3) | |
| IIIC | 26 (21.0) | 11 (8.7) | |
| Nuclear grade | |||
| 1, 2 | 85 (69.7) | 100 (79.4) | 0.0791 |
| 3 | 37 (30.3) | 26 (20.6) | |
| ER | |||
| Negative | 36 (29.0) | 40 (31.8) | 0.6409 |
| Positive | 88 (71.0) | 86 (68.2) | |
| PgR | |||
| Negative | 64 (51.6) | 66 (52.4) | 0.9033 |
| Positive | 60 (48.4) | 60 (47.6) | |
| HER2 | |||
| Negative | 75 (60.5) | 77 (61.1) | 0.9191 |
| Positive | 49 (39.5) | 49 (38.9) | |
| Subtypes | |||
| HR+/HER2− | 55 (44.4) | 56 (44.4) | 0.9313 |
| HR+/HER2+ | 35 (28.2) | 32 (25.4) | |
| HR−/HER2+ | 14 (11.3) | 17 813.9) | |
| TN | 20 (16.1) | 21 (16.7) | |
SE standard error, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Clinicopathological characteristics of the patients
| Factors | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 59 (28 to 75) |
| Menopausal status | |
| Pre/perimenopause | 135 (54.0) |
| Postmenopause | 115 (46.0) |
| Clinical stage | |
| I | 6 (2.4) |
| IIA | 73 (29.2) |
| IIB | 89 (35.6) |
| IIIA | 21 (8.4) |
| IIIB | 24 (9.6) |
| IIIC | 37 (14.8) |
| Nuclear grade | |
| 1, 2 | 185 (74.6) |
| 3 | 63 (25.4) |
| ER | |
| Negative | 76 (30.4) |
| Positive | 174 (69.6) |
| PgR | |
| Negative | 130 (52.0) |
| Positive | 120 (48.0) |
| HER2 | |
| Negative | 152 (60.8) |
| Positive | 98 (39.2) |
| Subtype | |
| HR+/HER2− | 111 (44.4) |
| HR+/HER2+ | 67 (26.8) |
| HR−/HER2+ | 31 (12.4) |
| TN | 41 (16.4) |
| Pathological efficacy | |
| pCR | 60 (24.0) |
| Non-pCR | 190 (76.0) |
| 25(OH)D | |
| Insufficient (< 20 ng/mL) | 241 (96.4) |
| Sufficient (≥ 20 ng/mL) | 9 (3.6) |
ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D
Relationships between serum 25(OH)D level and the efficacy of NAC
Results: Relationships between serum 25(OH)D level and the efficacy of NAC
Then, the relationships between the clinicopathological factors and the efficacy of NAC were analyzed (Table 3). The low clinical stage (I and II), PgR negativity (P < 0.0001) and HER2 positivity (P < 0.0001) were significantly associated with the higher achievement of pCR. The HR+ /HER2− subtype was associated with the lower achievement of pCR (P < 0.0001). However, there was no significant association between the serum 25(OH)D level and the pCR.
Relationships between the clinicopathological factors and pCR
| Non-pCR (n = 190) | pCR (n = 60) | P value | |
|---|---|---|---|
| Menopausal status | |||
| Pre/peri | 104 (54.7) | 31 (51.7) | 0.6776 |
| Post | 86 (45.3) | 29 (48.3) | |
| Clinical stage | |||
| I, II | 119 (62.6) | 49 (81.7) | 0.0045 |
| III | 71 (37.8) | 11 (18.3) | |
| ER | |||
| Negative | 52 (27.4) | 24 (40.0) | 0.0681 |
| Positive | 138 (72.6) | 36 (60.0) | |
| PgR | |||
| Negative | 83 (43.7) | 47 (78.3) | < 0.0001 |
| Positive | 107 (56.3) | 13 (21.7) | |
| HER2 | |||
| Negative | 131 (69.0) | 21 (35.0) | < 0.0001 |
| Positive | 59 (31.0) | 39 (65.0) | |
| Subtype | |||
| HR+/HER2− | 100 (52.6) | 11 (18.3) | < 0.0001 |
| HR+/HER2+ | 42 (22.1) | 25 (41.7) | |
| HR−/HER2+ | 17 (8.9) | 14 (23.3) | |
| TN | 31 (16.3) | 10 (16.7) | |
| 25(OH)D | |||
| Low | 97 (51.0) | 27 (45.0) | 0.4133 |
| High | 93 (49.0) | 33 (55.0) | |
ER estrogen receptor, PgR progesterone receptor, pCR pathological complete response, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Relationships between serum 25(OH)D level and the prognosis
Results: Relationships between serum 25(OH)D level and the prognosis
Then, the relationships between serum 25(OH)D levels and the prognosis were evaluated. In spite of no associations with the efficacy of NAC, the prognosis of the patients with the low serum 25(OH)D level was associated with poorer prognosis. The TTDR was significantly shorter in the patients with low 25(OH)D level (P = 0.0179), and the TTR and OS was poorer in the patients with low 25(OH)D level, although not statistically significant (Fig. 2). Relationship between the serum 25(OH)D level and the prognosis. A Time to recurrence, B time to distant recurrence, C overall survival. Red line: 25(OH)D low (n = 124), blue line: 25(OH)D high (n = 126)
Univariate and multivariate analyses of factors associated with TTDR
Results: Univariate and multivariate analyses of factors associated with TTDR
The clinicopathological factors possibly related to TTDR were analyzed by univariate and multivariate analyses (Table 4). According to the univariate analysis, high clinical stage before NAC (cStage III, P = 0.0165) and low serum 25(OH)D level (P = 0.0165) were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR (P = 0.037). According to a multivariate analysis that included these factors, high clinical stage (cStage III) and low serum 25(OH)D level were independent poor prognostic factors for TTDR (P = 0.0445 and P = 0.0231, Table 4).
Results of univariate and multivariate analyses for the TTDR
| Factors | Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P-value | ||
| Menopausal status | Pre/peri vs. post | 0.94 | 0.47 to 1.90 | 0.8673 | |||
| Clinical stage before NAC | III vs. I, II | 2.34 | 1.17 to 4.67 | 0.0165 | 2.05 | 1.01 to 4.10 | 0.0445 |
| ER | Positive vs. negative | 1.09 | 0.53 to 2.41 | 0.811 | |||
| PgR | Positive vs. negative | 1.05 | 0.53 to 2.09 | 0.8842 | |||
| HER2 | Positive vs. negative | 0.601 | 0.26 to 1.25 | 0.1799 | |||
| Tumor subtypes | HER2, TN vs. HR+ /HER2− | 0.57 | 0.28 to 1.12 | 0.1043 | |||
| Pathological efficacy | pCR vs. non-pCR | 0.34 | 0.08 to 0.94 | 0.037 | 0.39 | 0.09 to 1.13 | 0.087 |
| 25(OH)D | Low vs. high | 2.38 | 1.17 to 5.25 | 0.0165 | 2.28 | 1.12 to 5.03 | 0.0231 |
HR hazard ratio, CI confidence interval, TTDR time to distant recurrence, pCR pathological complete response, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Discussion
In the present study, we examined the relationships between the serum vitamin D (25(OH)D) levels and the pathological responses to NAC and the subsequent prognosis in Japanese women with operable breast cancer. There were no significant associations between the serum 25(OH)D levels and the pCR rate after NAC, however, the low serum 25(OH)D was significantly associated with the poor prognosis. As far as we know, this is the first study that investigated the association between the serum 25(OH)D levels and the efficacy of the NAC and the prognosis in the Japanese patients with breast cancer.
The association between vitamin D deficiency and the breast cancer risk and outcomes have been rigorously studied in Western countries, however, the data on the Asian women are lacking. For Japanese women, there is the only one case: control study using self-reported vitamin D intake, not serum 25(OD)D levels, which showed the significant inverse association with breast cancer [23]. In Korea, a large case: control study revealed that the deficient level of serum 25(OH)D was significantly associated with the breast cancer risk regardless of other breast cancer risk factors [24].
From these studies, vitamin D deficiency might be associated with the breast cancer risk in also Asian women.
In the Western countries, because there are lots of reports that showed the association between the vitamin D deficiency and the poor outcomes of breast cancer, the importance to intake sufficient vitamin D seems to have been recognized from an earlier time [7Not reported9, 12]. In a study from Canada, women with early-stage breast cancer diagnosed prior to 2005 frequently had low levels of vitamin D, however, women diagnosed in 2008 to 2009, vitamin D levels were higher, probably because of the use of vitamin D supplements [9] Although there are few data of Asian breast cancer patients, a very recent study from Thailand showed that low serum 25(OH)D level was found to be independently associated with poor survival in breast cancer patients, regardless of age, lymph node status, stage or breast cancer subtype [25].
The associations between the serum 25(OH)D levels and the pathological responses to NAC were inconsistent among studies. In the reports by Chiba et al. and Viala et al. from the same group, a significant association between the serum 25(OH)D levels and the pathological responses to NAC (pCR) was recognized [15, 16]. On the other hand, in the patients enrolled in NEOZOTAC phase III trial or the study conducted in Korea, baseline and end of NAC 25(OH)D levels and the changes of the 25(OH)D levels were not related to the pathological responses [17, 19].
The rate of the patients with sufficient 25(OH) D levels are different among studies. More than 60% of the patients were at the sufficient level in the study by Chiba et al. and Viala et al. and NEOZOTAC trial. However, 25(OH) D were at sufficient level in only 16.8% in the study of Kim et al. In NEOZOTAC trial, only patients with HER2− breast cancer were included and other studies included the patients with both HER2− and HER2+ patients. In addition, pCR rate was different among studies.
These factors might have influences on these inconsistencies.
In the present study, the low 25(OH)D was significantly associated with the poor prognosis and it was an independent poor prognostic factor by the multivariate analysis.
Surprisingly, serum 25(OH)D levels in most patients were insufficient (< 20 ng/mL) in our cohort. Serum 25(OH)D was positively associated with age, and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Because the vitamin D deficiency is associated with the breast carcinogenesis, and the subjects of this study were all breast cancer patients, the vitamin D levels might have been lower than that of the healthy Japanese women. The low 25(OH)D levels in the breast cancer patients were also recognized in other studies of the Asian women [19, 24, 25].
In the Korean study of NAC, the median 25(OH)D levels were also significantly lower than that of the women in the Western countries, and the sufficient levels were more often observed in postmenopausal women, which are similar to our results [19]. Only two postmenopausal patients received an analogue of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. The intake of these active vitamin D3 analog does not change the serum 25(OH)D level. Therefore, we think that the intake of active vitamin D3 analog had no effects of the result of this study.
As a consequence of indoor occupations and reduced exposure to sunlight, concerns for the vitamin D deficiency have been raised in developed countries [3, 4]. Also in Japan, females appear to be at higher risk of vitamin D deficiency because the younger people consume less fish than elders, they tend to avoid direct sunlight exposure to prevent skin-tanning, and they may be malnourished from maintaining a lean proportion [26Not reported30]. We showed here the relationship between the low vitamin D and the poor prognosis in the Japanese women with primary breast cancer for the first time.
We have not given the sufficient attention to the vitamin D in terms of the breast cancer risk and the prognosis in Japan. In addition, the analysis of 25(OH)D is not approved by the medical insurance in the ordinary practice of breast cancer in Japan. Therefore, the research regarding this theme might have not been done much in our country. We should pay more attention to vitamin D in regard to the cancer prevention and the prognosis.
The strength of the present study is that these data are form a single institution with high-quality follow-up and updated clinical data. However, these are several limitations associated with our study as well. All data are retrospective, and the duration of the follow-up was not sufficient. The number of the patients included in this study was small. In the present study, we included the only patients who underwent surgery after NAC. The cut-off value of the serum 25(OH)D was different from those in previous studies, most of which adopted 20 ng/mL as the cut off.
To elucidate the association between serum vitamin D and the outcome of the breast cancer, the study using the large cohort which include the patients with or without NAC is necessary.
In conclusion, serum vitamin D level at the baseline was not associated with pCR rate after NAC, however, low serum vitamin D level was significantly associated with the poor prognosis in Japanese women. Vitamin D is important not only for the bone metabolism, but also in the cancer risk and prognosis. Therefore, we should pay more attention to the vitamin D intake. It is a great interest that the supplement of vitamin D could improve the prognosis of the breast cancer patients.
Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: DiscussionResults
Patients’ characteristics
The clinicopathological characteristics of the patients included in this study were shown in Table 1. The median age was 59 years (range 28 to 75). Pre/peri-menopausal and postmenopausal women were 135 (54.0%) and 115 (46.0%), respectively. About 60% of the patients were at clinical stage II. The rate of ER, PgR and HER2-positivity was 69.6%, 48.0% and 39.2%, respectively. In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively.
Among the 250 patients, pCR was achieved in 60 (24.0%) patients.
Clinicopathological characteristics of the patients
| Factors | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 59 (28 to 75) |
| Menopausal status | |
| Pre/perimenopause | 135 (54.0) |
| Postmenopause | 115 (46.0) |
| Clinical stage | |
| I | 6 (2.4) |
| IIA | 73 (29.2) |
| IIB | 89 (35.6) |
| IIIA | 21 (8.4) |
| IIIB | 24 (9.6) |
| IIIC | 37 (14.8) |
| Nuclear grade | |
| 1, 2 | 185 (74.6) |
| 3 | 63 (25.4) |
| ER | |
| Negative | 76 (30.4) |
| Positive | 174 (69.6) |
| PgR | |
| Negative | 130 (52.0) |
| Positive | 120 (48.0) |
| HER2 | |
| Negative | 152 (60.8) |
| Positive | 98 (39.2) |
| Subtype | |
| HR+/HER2− | 111 (44.4) |
| HR+/HER2+ | 67 (26.8) |
| HR−/HER2+ | 31 (12.4) |
| TN | 41 (16.4) |
| Pathological efficacy | |
| pCR | 60 (24.0) |
| Non-pCR | 190 (76.0) |
| 25(OH)D | |
| Insufficient (< 20 ng/mL) | 241 (96.4) |
| Sufficient (≥ 20 ng/mL) | 9 (3.6) |
ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D
Relationships between the serum 25(OH)D level and the clinicopathological characteristics
The median 25(OH)D levels were 10.7 ng/mL (range 3.0 to 26.6 ng/mL). Surprisingly, serum 25(OH)D was sufficient in only nine patients (3.6%) in this cohort (Table 1). Serum 25(OH)D was positively associated with age (P = 0.0016), and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women (P = 0.0020, Fig. 1). In the present study, serum 25(OH)D level was divided into two groups, low and high, using a dichotomous variable at the median value 10.7 ng/mL.
Relationships between the serum 25(OH)D level and the clinicopathological characteristics were shown in Table 2. The median age of the high 25(OH)D group was significantly higher than that of the low 25(OH)D group (52.7 ± 0.93 year old vs. 48.5 ± 0.93, P = 0.0015), and the number of the postmenopausal women was significantly higher in the high 25(OH)D group (P = 0.0022). There were no significant associations between serum 25(OH)D level and the clinical stage, ER and PgR expressions, HER2 status and tumor subtypes. Relationship between age and menopausal status and the serum 25(OH)D level. A Relationship between age and the serum 25(OH)D level. B Relationship between menopausal status and the 25(OH)D level
Relationships between the clinicopathological characteristics and the serum 25(OH)D level
| Factors | 25(OH)D low (n = 124) | 25(OH)D high (n = 126) | P value |
|---|---|---|---|
| Age (years) | |||
| Mean ± SE | 48.5 ± 0.93 | 52.7 ± 0.93 | 0.0015 |
| Menopausal status | |||
| Pre/perimenopause | 79 (63.7) | 56 (44.4) | 0.0022 |
| Postmenopause | 45 (36.3) | 70 (55.6) | |
| Clinical stage | |||
| I | 2 (1.6) | 4 (3.2) | 0.147 |
| IIA | 35 (28.3) | 38 (30.2) | |
| IIB | 40 (32.3) | 49 (38.9) | |
| IIIA | 10 (8.1) | 11 (8.7) | |
| IIIB | 11 (8.9) | 13 (10.3) | |
| IIIC | 26 (21.0) | 11 (8.7) | |
| Nuclear grade | |||
| 1, 2 | 85 (69.7) | 100 (79.4) | 0.0791 |
| 3 | 37 (30.3) | 26 (20.6) | |
| ER | |||
| Negative | 36 (29.0) | 40 (31.8) | 0.6409 |
| Positive | 88 (71.0) | 86 (68.2) | |
| PgR | |||
| Negative | 64 (51.6) | 66 (52.4) | 0.9033 |
| Positive | 60 (48.4) | 60 (47.6) | |
| HER2 | |||
| Negative | 75 (60.5) | 77 (61.1) | 0.9191 |
| Positive | 49 (39.5) | 49 (38.9) | |
| Subtypes | |||
| HR+/HER2− | 55 (44.4) | 56 (44.4) | 0.9313 |
| HR+/HER2+ | 35 (28.2) | 32 (25.4) | |
| HR−/HER2+ | 14 (11.3) | 17 813.9) | |
| TN | 20 (16.1) | 21 (16.7) | |
SE standard error, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Relationships between serum 25(OH)D level and the efficacy of NAC
Then, the relationships between the clinicopathological factors and the efficacy of NAC were analyzed (Table 3). The low clinical stage (I and II), PgR negativity (P < 0.0001) and HER2 positivity (P < 0.0001) were significantly associated with the higher achievement of pCR. The HR+ /HER2− subtype was associated with the lower achievement of pCR (P < 0.0001). However, there was no significant association between the serum 25(OH)D level and the pCR.
Relationships between the clinicopathological factors and pCR
| Non-pCR (n = 190) | pCR (n = 60) | P value | |
|---|---|---|---|
| Menopausal status | |||
| Pre/peri | 104 (54.7) | 31 (51.7) | 0.6776 |
| Post | 86 (45.3) | 29 (48.3) | |
| Clinical stage | |||
| I, II | 119 (62.6) | 49 (81.7) | 0.0045 |
| III | 71 (37.8) | 11 (18.3) | |
| ER | |||
| Negative | 52 (27.4) | 24 (40.0) | 0.0681 |
| Positive | 138 (72.6) | 36 (60.0) | |
| PgR | |||
| Negative | 83 (43.7) | 47 (78.3) | < 0.0001 |
| Positive | 107 (56.3) | 13 (21.7) | |
| HER2 | |||
| Negative | 131 (69.0) | 21 (35.0) | < 0.0001 |
| Positive | 59 (31.0) | 39 (65.0) | |
| Subtype | |||
| HR+/HER2− | 100 (52.6) | 11 (18.3) | < 0.0001 |
| HR+/HER2+ | 42 (22.1) | 25 (41.7) | |
| HR−/HER2+ | 17 (8.9) | 14 (23.3) | |
| TN | 31 (16.3) | 10 (16.7) | |
| 25(OH)D | |||
| Low | 97 (51.0) | 27 (45.0) | 0.4133 |
| High | 93 (49.0) | 33 (55.0) | |
ER estrogen receptor, PgR progesterone receptor, pCR pathological complete response, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Relationships between serum 25(OH)D level and the prognosis
Then, the relationships between serum 25(OH)D levels and the prognosis were evaluated. In spite of no associations with the efficacy of NAC, the prognosis of the patients with the low serum 25(OH)D level was associated with poorer prognosis. The TTDR was significantly shorter in the patients with low 25(OH)D level (P = 0.0179), and the TTR and OS was poorer in the patients with low 25(OH)D level, although not statistically significant (Fig. 2). Relationship between the serum 25(OH)D level and the prognosis. A Time to recurrence, B time to distant recurrence, C overall survival. Red line: 25(OH)D low (n = 124), blue line: 25(OH)D high (n = 126)
Univariate and multivariate analyses of factors associated with TTDR
The clinicopathological factors possibly related to TTDR were analyzed by univariate and multivariate analyses (Table 4). According to the univariate analysis, high clinical stage before NAC (cStage III, P = 0.0165) and low serum 25(OH)D level (P = 0.0165) were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR (P = 0.037). According to a multivariate analysis that included these factors, high clinical stage (cStage III) and low serum 25(OH)D level were independent poor prognostic factors for TTDR (P = 0.0445 and P = 0.0231, Table 4).
Results of univariate and multivariate analyses for the TTDR
| Factors | Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P-value | ||
| Menopausal status | Pre/peri vs. post | 0.94 | 0.47 to 1.90 | 0.8673 | |||
| Clinical stage before NAC | III vs. I, II | 2.34 | 1.17 to 4.67 | 0.0165 | 2.05 | 1.01 to 4.10 | 0.0445 |
| ER | Positive vs. negative | 1.09 | 0.53 to 2.41 | 0.811 | |||
| PgR | Positive vs. negative | 1.05 | 0.53 to 2.09 | 0.8842 | |||
| HER2 | Positive vs. negative | 0.601 | 0.26 to 1.25 | 0.1799 | |||
| Tumor subtypes | HER2, TN vs. HR+ /HER2− | 0.57 | 0.28 to 1.12 | 0.1043 | |||
| Pathological efficacy | pCR vs. non-pCR | 0.34 | 0.08 to 0.94 | 0.037 | 0.39 | 0.09 to 1.13 | 0.087 |
| 25(OH)D | Low vs. high | 2.38 | 1.17 to 5.25 | 0.0165 | 2.28 | 1.12 to 5.03 | 0.0231 |
HR hazard ratio, CI confidence interval, TTDR time to distant recurrence, pCR pathological complete response, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Abstract: Conclusions
The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.
Source: ConclusionsAuthors’ abstract
Background
Several studies have recently reported that the relationships between serum vitamin D and the prognosis or the pathological response to neoadjuvant chemotherapy (NAC) in breast cancer. However, there are no data regarding the clinical impacts of the vitamin D in Japanese breast cancer patients so far.
Patients and methods
In the present study, a total of 250 patients with clinical Stage I: III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery were included. Serum 25-hydroxvitamin D (25(OH)D) levels were evaluated using blood samples obtained before NAC.
Results
The serum 25(OH)D was positively associated with age, and the serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Serum 25(OH)D level was not associated with the achievement of pathological complete response (pCR) in this cohort. The low 25(OH)D levels were significantly associated with shorter time to distant recurrence (TTDR). According to the univariate analysis, high clinical stage before NAC (cStage III) and low serum 25(OH)D level were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR.
According to a multivariate analysis, low serum 25(OH)D level were independent poor prognostic factors for TTDR.
Conclusions
The low 25(OH)D levels were significantly associated with poorer prognosis in Japanese women with operable breast cancer patients treated with NAC.
Read the full paper
Introduction
Vitamin D is a fat-soluble secosteroid with well-established effects on calcium homeostasis, and it is the precursor to the potent steroid hormone calcitriol [1, 2]. Deficiency of vitamin D is associated with increased risks of morbidity and mortality in various diseases including cardiovascular, malignant, and autoimmune diseases [2Not reported5]. Vitamin D regulates numerous cellular pathways such as inhibition of cellular proliferation, inflammation, invasion, metastasis and angiogenesis, and also promotion of apoptosis and differentiation [2].
One of those mechanisms is the intervention on the cell cycle via kinases such as cyclins, cyclin-dependent kinases (CDKs) and CDK physiological modulators [6]. Previous studies have revealed that the vitamin D deficiency was associated with poor outcomes in breast cancer [7Not reported9], although contradictory results have also been reported [10, 11].
25-hydroxvitamin D (25(OH)D) is the circulating form of vitamin D that is measured in the blood and clinically used to establish and monitor the vitamin D status. One study showed that the serum 25(OH)D levels could predict cancer survival in a prospective cohort with measurements prior to and at the time of cancer diagnosis [12].
Neoadjuvant chemotherapy (NAC) has become a standard of care not only in locally advanced breast cancer, but in early breast cancer, especially for patients with large tumor size, lymph node metastasis, HER2 overexpression and triple negative breast cancer (TNBC) subtype. Pathological complete response (pCR) is associated with improved prognosis. This association appears stronger in the HER2+ /hormone receptor (HR): or TNBC subtype [13, 14].
Recently, a statistically significant association between 25(OH)D level at baseline and pCR in patients with receiving NAC has been reported [15, 16]. However, other studies reported that there was no effect of serum 25(OH)D levels on the pathologic complete response (pCR) in neoadjuvant settings [17Not reported19].
Recent reports shows that East Asian countries have high prevalence rates of Vit D deficiency [20, 21]. However, in Japan, the importance of the vitamin D on the incidence of cancer or the prognosis of the patients with malignancies has not been recognized so much. There are few studies on the association between serum vitamin D levels and the clinicopathological features and the prognosis of the Japanese women with breast cancer. In the present study, we retrospectively compared serum 25(OH)D level at baseline and the efficacy of NAC and the prognosis after surgery.
Patients and methods
Patient population
A total of 250 patients with clinical Stage I: III primary breast cancer who were treated with NAC and subsequently underwent definitive surgery of the breast and axilla in the Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, between 2009 and 2019 were included in this study. Chemotherapy was administered according to the standard regimens of anthracyclines and/or taxanes with or without trastuzumab for HER2-positive (HER2+) breast cancer. For all these patients, serum obtained just before starting NAC was available.
The clinical data were obtained from the patients’ medical records. The anatomical AJCC/UICC TNM classification and stage groupings were used. This study was approved by the institutional review board of our hospital, and was in accordance with the Declaration of Helsinki. The serum was the surplus sample from the usual blood test. We obtained the written informed general consent from an individual patient before the start of the treatment and the sample acquisition. Our IRB waived the requirement for obtaining another written informed consent when we use the surplus samples.
Pathological examinations
All pathological examinations were performed by the experienced pathologists in our hospital. The expression of estrogen receptor (ER) and progesterone receptor (PgR) was regarded as positive if the nuclear expression was ≥ 1%. The HER2 status was evaluated according to the recommendation of ASCO/CAP [22]. The pCR was regarded as the total disappearance of invasive carcinoma cells, including lymph nodes, regardless of the presence of residual ductal carcinoma in situ. If ER and /or PgR were positive, it was defined HR-positive (HR+).
The tumor subtypes were divided into the following four groups; HR+ /HER2−, HR+ /HER2+ , HR−/HER2+ and triple negative (TN; ER−, PgR− and HER2−).
Serum vitamin D (25-hydroxyvitamin D; 25(OH)D) levels
Serum samples obtained before the first cycle of NAC were stored at − 30 °C until analysis. Serum 25(OH)D levels were analyzed by ELISA at SRL laboratories (Tokyo, Japan). Serum 25(OH)D levels were defined as ‘sufficient’ if serum 25(OH)D ≥ 20 ng/mL and ‘insufficient’ if serum 25(OH)D < 20 ng/mL [2, 19].
Statistical analyses
The statistical analyses were performed using the JMP software package, version 14.0 (SAS Institute Inc., Cary, NC, USA). The associations between the clinicopathological characteristics were assessed using χ2 tests. The time to recurrence (TTR) was defined as the time from surgery to the first breast cancer event, including loco-regional recurrence, distant metastasis or a new cancer in the contralateral breast. The time to distant recurrence (TTDR) was defined as the time from the date of curative surgery to the detection of distant recurrence.
The overall survival (OS) was defined as the time from the date of curative surgery to death. Survival curves were plotted using the Kaplan: Meier method, and the association between the survival and each variable was determined by the log-rank test. For multivariate analysis of the survival data, Cox proportional hazards model was used. Differences were considered to be significant at P < 0.05.
Results
Patients’ characteristics
The clinicopathological characteristics of the patients included in this study were shown in Table 1. The median age was 59 years (range 28 to 75). Pre/peri-menopausal and postmenopausal women were 135 (54.0%) and 115 (46.0%), respectively. About 60% of the patients were at clinical stage II. The rate of ER, PgR and HER2-positivity was 69.6%, 48.0% and 39.2%, respectively. In terms of tumor subtypes, HR+ /HER2− were 111 (44.4%), HR+ /HER2+ 67 (26.8%), HR−/HER2+ 31 (12.4%) and TN 41 (16.4%), respectively.
Among the 250 patients, pCR was achieved in 60 (24.0%) patients.
Clinicopathological characteristics of the patients
| Factors | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 59 (28 to 75) |
| Menopausal status | |
| Pre/perimenopause | 135 (54.0) |
| Postmenopause | 115 (46.0) |
| Clinical stage | |
| I | 6 (2.4) |
| IIA | 73 (29.2) |
| IIB | 89 (35.6) |
| IIIA | 21 (8.4) |
| IIIB | 24 (9.6) |
| IIIC | 37 (14.8) |
| Nuclear grade | |
| 1, 2 | 185 (74.6) |
| 3 | 63 (25.4) |
| ER | |
| Negative | 76 (30.4) |
| Positive | 174 (69.6) |
| PgR | |
| Negative | 130 (52.0) |
| Positive | 120 (48.0) |
| HER2 | |
| Negative | 152 (60.8) |
| Positive | 98 (39.2) |
| Subtype | |
| HR+/HER2− | 111 (44.4) |
| HR+/HER2+ | 67 (26.8) |
| HR−/HER2+ | 31 (12.4) |
| TN | 41 (16.4) |
| Pathological efficacy | |
| pCR | 60 (24.0) |
| Non-pCR | 190 (76.0) |
| 25(OH)D | |
| Insufficient (< 20 ng/mL) | 241 (96.4) |
| Sufficient (≥ 20 ng/mL) | 9 (3.6) |
ER: estrogen receptor, PgR: progesterone receptor, pCR: pathological complete response, HR: hormone receptor, TN: triple-negative, 25(OH)D: 25-hydroxyvitamin D
Relationships between the serum 25(OH)D level and the clinicopathological characteristics
The median 25(OH)D levels were 10.7 ng/mL (range 3.0 to 26.6 ng/mL). Surprisingly, serum 25(OH)D was sufficient in only nine patients (3.6%) in this cohort (Table 1). Serum 25(OH)D was positively associated with age (P = 0.0016), and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women (P = 0.0020, Fig. 1). In the present study, serum 25(OH)D level was divided into two groups, low and high, using a dichotomous variable at the median value 10.7 ng/mL.
Relationships between the serum 25(OH)D level and the clinicopathological characteristics were shown in Table 2. The median age of the high 25(OH)D group was significantly higher than that of the low 25(OH)D group (52.7 ± 0.93 year old vs. 48.5 ± 0.93, P = 0.0015), and the number of the postmenopausal women was significantly higher in the high 25(OH)D group (P = 0.0022). There were no significant associations between serum 25(OH)D level and the clinical stage, ER and PgR expressions, HER2 status and tumor subtypes. Relationship between age and menopausal status and the serum 25(OH)D level. A Relationship between age and the serum 25(OH)D level. B Relationship between menopausal status and the 25(OH)D level
Relationships between the clinicopathological characteristics and the serum 25(OH)D level
| Factors | 25(OH)D low (n = 124) | 25(OH)D high (n = 126) | P value |
|---|---|---|---|
| Age (years) | |||
| Mean ± SE | 48.5 ± 0.93 | 52.7 ± 0.93 | 0.0015 |
| Menopausal status | |||
| Pre/perimenopause | 79 (63.7) | 56 (44.4) | 0.0022 |
| Postmenopause | 45 (36.3) | 70 (55.6) | |
| Clinical stage | |||
| I | 2 (1.6) | 4 (3.2) | 0.147 |
| IIA | 35 (28.3) | 38 (30.2) | |
| IIB | 40 (32.3) | 49 (38.9) | |
| IIIA | 10 (8.1) | 11 (8.7) | |
| IIIB | 11 (8.9) | 13 (10.3) | |
| IIIC | 26 (21.0) | 11 (8.7) | |
| Nuclear grade | |||
| 1, 2 | 85 (69.7) | 100 (79.4) | 0.0791 |
| 3 | 37 (30.3) | 26 (20.6) | |
| ER | |||
| Negative | 36 (29.0) | 40 (31.8) | 0.6409 |
| Positive | 88 (71.0) | 86 (68.2) | |
| PgR | |||
| Negative | 64 (51.6) | 66 (52.4) | 0.9033 |
| Positive | 60 (48.4) | 60 (47.6) | |
| HER2 | |||
| Negative | 75 (60.5) | 77 (61.1) | 0.9191 |
| Positive | 49 (39.5) | 49 (38.9) | |
| Subtypes | |||
| HR+/HER2− | 55 (44.4) | 56 (44.4) | 0.9313 |
| HR+/HER2+ | 35 (28.2) | 32 (25.4) | |
| HR−/HER2+ | 14 (11.3) | 17 813.9) | |
| TN | 20 (16.1) | 21 (16.7) | |
SE standard error, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Relationships between serum 25(OH)D level and the efficacy of NAC
Then, the relationships between the clinicopathological factors and the efficacy of NAC were analyzed (Table 3). The low clinical stage (I and II), PgR negativity (P < 0.0001) and HER2 positivity (P < 0.0001) were significantly associated with the higher achievement of pCR. The HR+ /HER2− subtype was associated with the lower achievement of pCR (P < 0.0001). However, there was no significant association between the serum 25(OH)D level and the pCR.
Relationships between the clinicopathological factors and pCR
| Non-pCR (n = 190) | pCR (n = 60) | P value | |
|---|---|---|---|
| Menopausal status | |||
| Pre/peri | 104 (54.7) | 31 (51.7) | 0.6776 |
| Post | 86 (45.3) | 29 (48.3) | |
| Clinical stage | |||
| I, II | 119 (62.6) | 49 (81.7) | 0.0045 |
| III | 71 (37.8) | 11 (18.3) | |
| ER | |||
| Negative | 52 (27.4) | 24 (40.0) | 0.0681 |
| Positive | 138 (72.6) | 36 (60.0) | |
| PgR | |||
| Negative | 83 (43.7) | 47 (78.3) | < 0.0001 |
| Positive | 107 (56.3) | 13 (21.7) | |
| HER2 | |||
| Negative | 131 (69.0) | 21 (35.0) | < 0.0001 |
| Positive | 59 (31.0) | 39 (65.0) | |
| Subtype | |||
| HR+/HER2− | 100 (52.6) | 11 (18.3) | < 0.0001 |
| HR+/HER2+ | 42 (22.1) | 25 (41.7) | |
| HR−/HER2+ | 17 (8.9) | 14 (23.3) | |
| TN | 31 (16.3) | 10 (16.7) | |
| 25(OH)D | |||
| Low | 97 (51.0) | 27 (45.0) | 0.4133 |
| High | 93 (49.0) | 33 (55.0) | |
ER estrogen receptor, PgR progesterone receptor, pCR pathological complete response, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Relationships between serum 25(OH)D level and the prognosis
Then, the relationships between serum 25(OH)D levels and the prognosis were evaluated. In spite of no associations with the efficacy of NAC, the prognosis of the patients with the low serum 25(OH)D level was associated with poorer prognosis. The TTDR was significantly shorter in the patients with low 25(OH)D level (P = 0.0179), and the TTR and OS was poorer in the patients with low 25(OH)D level, although not statistically significant (Fig. 2). Relationship between the serum 25(OH)D level and the prognosis. A Time to recurrence, B time to distant recurrence, C overall survival. Red line: 25(OH)D low (n = 124), blue line: 25(OH)D high (n = 126)
Univariate and multivariate analyses of factors associated with TTDR
The clinicopathological factors possibly related to TTDR were analyzed by univariate and multivariate analyses (Table 4). According to the univariate analysis, high clinical stage before NAC (cStage III, P = 0.0165) and low serum 25(OH)D level (P = 0.0165) were significantly associated with the shorter TTDR, and pCR was significantly associated with the longer TTDR (P = 0.037). According to a multivariate analysis that included these factors, high clinical stage (cStage III) and low serum 25(OH)D level were independent poor prognostic factors for TTDR (P = 0.0445 and P = 0.0231, Table 4).
Results of univariate and multivariate analyses for the TTDR
| Factors | Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P-value | ||
| Menopausal status | Pre/peri vs. post | 0.94 | 0.47 to 1.90 | 0.8673 | |||
| Clinical stage before NAC | III vs. I, II | 2.34 | 1.17 to 4.67 | 0.0165 | 2.05 | 1.01 to 4.10 | 0.0445 |
| ER | Positive vs. negative | 1.09 | 0.53 to 2.41 | 0.811 | |||
| PgR | Positive vs. negative | 1.05 | 0.53 to 2.09 | 0.8842 | |||
| HER2 | Positive vs. negative | 0.601 | 0.26 to 1.25 | 0.1799 | |||
| Tumor subtypes | HER2, TN vs. HR+ /HER2− | 0.57 | 0.28 to 1.12 | 0.1043 | |||
| Pathological efficacy | pCR vs. non-pCR | 0.34 | 0.08 to 0.94 | 0.037 | 0.39 | 0.09 to 1.13 | 0.087 |
| 25(OH)D | Low vs. high | 2.38 | 1.17 to 5.25 | 0.0165 | 2.28 | 1.12 to 5.03 | 0.0231 |
HR hazard ratio, CI confidence interval, TTDR time to distant recurrence, pCR pathological complete response, ER estrogen receptor, PgR progesterone receptor, HR hormone receptor, TN triple-negative, 25(OH)D 25-hydroxyvitamin D
Discussion
In the present study, we examined the relationships between the serum vitamin D (25(OH)D) levels and the pathological responses to NAC and the subsequent prognosis in Japanese women with operable breast cancer. There were no significant associations between the serum 25(OH)D levels and the pCR rate after NAC, however, the low serum 25(OH)D was significantly associated with the poor prognosis. As far as we know, this is the first study that investigated the association between the serum 25(OH)D levels and the efficacy of the NAC and the prognosis in the Japanese patients with breast cancer.
The association between vitamin D deficiency and the breast cancer risk and outcomes have been rigorously studied in Western countries, however, the data on the Asian women are lacking. For Japanese women, there is the only one case: control study using self-reported vitamin D intake, not serum 25(OD)D levels, which showed the significant inverse association with breast cancer [23]. In Korea, a large case: control study revealed that the deficient level of serum 25(OH)D was significantly associated with the breast cancer risk regardless of other breast cancer risk factors [24].
From these studies, vitamin D deficiency might be associated with the breast cancer risk in also Asian women.
In the Western countries, because there are lots of reports that showed the association between the vitamin D deficiency and the poor outcomes of breast cancer, the importance to intake sufficient vitamin D seems to have been recognized from an earlier time [7Not reported9, 12]. In a study from Canada, women with early-stage breast cancer diagnosed prior to 2005 frequently had low levels of vitamin D, however, women diagnosed in 2008 to 2009, vitamin D levels were higher, probably because of the use of vitamin D supplements [9] Although there are few data of Asian breast cancer patients, a very recent study from Thailand showed that low serum 25(OH)D level was found to be independently associated with poor survival in breast cancer patients, regardless of age, lymph node status, stage or breast cancer subtype [25].
The associations between the serum 25(OH)D levels and the pathological responses to NAC were inconsistent among studies. In the reports by Chiba et al. and Viala et al. from the same group, a significant association between the serum 25(OH)D levels and the pathological responses to NAC (pCR) was recognized [15, 16]. On the other hand, in the patients enrolled in NEOZOTAC phase III trial or the study conducted in Korea, baseline and end of NAC 25(OH)D levels and the changes of the 25(OH)D levels were not related to the pathological responses [17, 19].
The rate of the patients with sufficient 25(OH) D levels are different among studies. More than 60% of the patients were at the sufficient level in the study by Chiba et al. and Viala et al. and NEOZOTAC trial. However, 25(OH) D were at sufficient level in only 16.8% in the study of Kim et al. In NEOZOTAC trial, only patients with HER2− breast cancer were included and other studies included the patients with both HER2− and HER2+ patients. In addition, pCR rate was different among studies.
These factors might have influences on these inconsistencies.
In the present study, the low 25(OH)D was significantly associated with the poor prognosis and it was an independent poor prognostic factor by the multivariate analysis.
Surprisingly, serum 25(OH)D levels in most patients were insufficient (< 20 ng/mL) in our cohort. Serum 25(OH)D was positively associated with age, and serum 25(OH)D was significantly higher in postmenopausal women than that in pre/peri-menopausal women. Because the vitamin D deficiency is associated with the breast carcinogenesis, and the subjects of this study were all breast cancer patients, the vitamin D levels might have been lower than that of the healthy Japanese women. The low 25(OH)D levels in the breast cancer patients were also recognized in other studies of the Asian women [19, 24, 25].
In the Korean study of NAC, the median 25(OH)D levels were also significantly lower than that of the women in the Western countries, and the sufficient levels were more often observed in postmenopausal women, which are similar to our results [19]. Only two postmenopausal patients received an analogue of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. The intake of these active vitamin D3 analog does not change the serum 25(OH)D level. Therefore, we think that the intake of active vitamin D3 analog had no effects of the result of this study.
As a consequence of indoor occupations and reduced exposure to sunlight, concerns for the vitamin D deficiency have been raised in developed countries [3, 4]. Also in Japan, females appear to be at higher risk of vitamin D deficiency because the younger people consume less fish than elders, they tend to avoid direct sunlight exposure to prevent skin-tanning, and they may be malnourished from maintaining a lean proportion [26Not reported30]. We showed here the relationship between the low vitamin D and the poor prognosis in the Japanese women with primary breast cancer for the first time.
We have not given the sufficient attention to the vitamin D in terms of the breast cancer risk and the prognosis in Japan. In addition, the analysis of 25(OH)D is not approved by the medical insurance in the ordinary practice of breast cancer in Japan. Therefore, the research regarding this theme might have not been done much in our country. We should pay more attention to vitamin D in regard to the cancer prevention and the prognosis.
The strength of the present study is that these data are form a single institution with high-quality follow-up and updated clinical data. However, these are several limitations associated with our study as well. All data are retrospective, and the duration of the follow-up was not sufficient. The number of the patients included in this study was small. In the present study, we included the only patients who underwent surgery after NAC. The cut-off value of the serum 25(OH)D was different from those in previous studies, most of which adopted 20 ng/mL as the cut off.
To elucidate the association between serum vitamin D and the outcome of the breast cancer, the study using the large cohort which include the patients with or without NAC is necessary.
In conclusion, serum vitamin D level at the baseline was not associated with pCR rate after NAC, however, low serum vitamin D level was significantly associated with the poor prognosis in Japanese women. Vitamin D is important not only for the bone metabolism, but also in the cancer risk and prognosis. Therefore, we should pay more attention to the vitamin D intake. It is a great interest that the supplement of vitamin D could improve the prognosis of the breast cancer patients.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Acknowledgements
We thank Ms. Kimiko Baba, Ms. Maki Tanaka and Ms. Yumiko Tatesaka for their valuable assistance.
Declarations
Conflict of interest
Eriko Tokunaga received lecture fee from Chugai, AstraZeneca and Eli Lilly. Other authors declare no conflict of interest.
References
Publication and source details
Original title: Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Eriko Tokunaga; Takanobu Masuda; Hideki Ijichi; Wakako Tajiri; Chinami Koga; Yumiko Koi; Yoshiaki Nakamura; Shinji Ohno; Kenichi Taguchi; Masahiro Okamoto
Breast Cancer (Tokyo, Japan) · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T11:15:33.184795+00:00
DOI: 10.1007/s12282-021-01292-3 · PMC8732931